According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “
OSMT has been the topic of a number of other research reports. Barclays assumed coverage on shares of Osmotica Pharmaceuticals in a report on Tuesday, June 11th. They set an overweight rating and a $11.00 price target on the stock. ValuEngine upgraded shares of Osmotica Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 1st. Wells Fargo & Co reissued a buy rating on shares of Osmotica Pharmaceuticals in a report on Friday, August 9th. Finally, Jefferies Financial Group set a $10.00 price objective on shares of Osmotica Pharmaceuticals and gave the company a buy rating in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Osmotica Pharmaceuticals has a consensus rating of Buy and a consensus target price of $13.00.
Osmotica Pharmaceuticals stock opened at $3.20 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.78 and a quick ratio of 1.49. Osmotica Pharmaceuticals has a one year low of $2.20 and a one year high of $9.90. The stock has a market capitalization of $154.56 million and a PE ratio of -6.27. The business’s fifty day moving average is $3.09 and its 200 day moving average is $3.90.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.06. Osmotica Pharmaceuticals had a negative return on equity of 32.14% and a negative net margin of 97.91%. The company had revenue of $57.53 million during the quarter, compared to the consensus estimate of $57.90 million. As a group, sell-side analysts expect that Osmotica Pharmaceuticals will post -0.25 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Sofinnova Investments Inc. grew its holdings in shares of Osmotica Pharmaceuticals by 107.5% in the second quarter. Sofinnova Investments Inc. now owns 525,198 shares of the company’s stock worth $1,996,000 after acquiring an additional 272,109 shares during the period. Northern Trust Corp increased its position in Osmotica Pharmaceuticals by 5.6% during the second quarter. Northern Trust Corp now owns 99,449 shares of the company’s stock valued at $378,000 after acquiring an additional 5,230 shares during the last quarter. Geode Capital Management LLC bought a new position in Osmotica Pharmaceuticals in the fourth quarter valued at about $668,000. Acadian Asset Management LLC lifted its holdings in Osmotica Pharmaceuticals by 277.5% in the second quarter. Acadian Asset Management LLC now owns 53,846 shares of the company’s stock valued at $206,000 after acquiring an additional 39,584 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Osmotica Pharmaceuticals in the second quarter worth about $142,000. Hedge funds and other institutional investors own 7.01% of the company’s stock.
About Osmotica Pharmaceuticals
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Further Reading: How to Invest in the Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.